Press Releases

Date Title and Summary Additional Formats
Toggle Summary Conatus Pharmaceuticals Announces Poster Presentation at AASLD Annual Meeting
Pan-caspase Inhibitor IDN-7314 Reduces Liver Injury Due to Intestinal Bacteria Imbalance Resulting from Restricted Bile Flow in Mouse Model of PSC
View HTML
Toggle Summary EMA Grants Conatus Orphan Drug Designation for IDN-7314 for the Treatment of PSC
SAN DIEGO, Oct. 18, 2017 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) today announced that the European Medicines Agency (EMA) has granted orphan designation to Conatus' drug candidate IDN-7314 for the treatment of primary sclerosing cholangitis (PSC), a disease affecting bile
View HTML
Toggle Summary Conatus Pharmaceuticals Appoints Keith W. Marshall as Executive Vice President, Chief Operating Officer and Chief Financial Officer
SAN DIEGO, Aug. 31, 2017 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (NASDAQ:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced the appointment of Keith W. Marshall, Ph.D., M.B.A., as Executive Vice
View HTML
Toggle Summary Conatus to Present at Rodman & Renshaw Global Investment Conference
SAN DIEGO, Aug. 29, 2017 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced its scheduled presentation to provide an overview of the company's programs and outlook at the Rodman & Renshaw 19 th Annual Global Investment Conference in New York at 11:15 a.m.
View HTML
Toggle Summary Conatus Announces Completion of Enrollment in ENCORE-NF Phase 2b Clinical Trial of Emricasan in Patients with NASH Fibrosis
SAN DIEGO, Aug. 14, 2017 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced the completion of enrollment in ENCORE-NF, a randomized, double-blind, placebo-controlled, Phase 2b clinical trial evaluating emricasan, the company's first-in-class, orally-active pan-caspase
View HTML
Toggle Summary Conatus Pharmaceuticals Reports Second Quarter 2017 Financial Results and Program Updates
SAN DIEGO, Aug. 02, 2017 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced financial results for the quarter and six months ended June 30, 2017, and
View HTML
Toggle Summary Conatus Pharmaceuticals to Report Second Quarter 2017 Financial Results
SAN DIEGO, July 26, 2017 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced that it will report financial results for the second quarter ended June 30, 2017, after the market close on Wednesday, August 2, 2017. Conatus will host a conference call and audio webcast at
View HTML
Toggle Summary Conatus Announces Effectiveness of Exclusive License for Global Development and Commercialization of Emricasan with Receipt of $7 Million Payment
SAN DIEGO, July 06, 2017 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced that its exclusive license with Novartis for the global development and commercialization of emricasan has become effective under terms of the Option, Collaboration and License Agreement signed
View HTML
Toggle Summary FDA Grants Conatus Orphan Drug Designation for IDN-7314 for the Treatment of PSC
SAN DIEGO, June 26, 2017 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to Conatus' drug candidate IDN-7314 for the treatment of primary sclerosing cholangitis (PSC), a disease
View HTML
Toggle Summary Conatus Pharmaceuticals Announces Poster Presentation at International Liver Cell Conference
Emricasan Improves and Sustains Key Functions in Cirrhotic Liver Cells
View HTML